Retinitis pigmentosa
- PMID: 17113430
- DOI: 10.1016/S0140-6736(06)69740-7
Retinitis pigmentosa
Abstract
Hereditary degenerations of the human retina are genetically heterogeneous, with well over 100 genes implicated so far. This Seminar focuses on the subset of diseases called retinitis pigmentosa, in which patients typically lose night vision in adolescence, side vision in young adulthood, and central vision in later life because of progressive loss of rod and cone photoreceptor cells. Measures of retinal function, such as the electroretinogram, show that photoreceptor function is diminished generally many years before symptomic night blindness, visual-field scotomas, or decreased visual acuity arise. More than 45 genes for retinitis pigmentosa have been identified. These genes account for only about 60% of all patients; the remainder have defects in as yet unidentified genes. Findings of controlled trials indicate that nutritional interventions, including vitamin A palmitate and omega-3-rich fish, slow progression of disease in many patients. Imminent treatments for retinitis pigmentosa are greatly anticipated, especially for genetically defined subsets of patients, because of newly identified genes, growing knowledge of affected biochemical pathways, and development of animal models.
Similar articles
-
Further evaluation of docosahexaenoic acid in patients with retinitis pigmentosa receiving vitamin A treatment: subgroup analyses.Arch Ophthalmol. 2004 Sep;122(9):1306-14. doi: 10.1001/archopht.122.9.1306. Arch Ophthalmol. 2004. PMID: 15364709 Clinical Trial.
-
Concentric retinitis pigmentosa: clinicopathologic correlations.Exp Eye Res. 2001 Oct;73(4):493-508. doi: 10.1006/exer.2001.1059. Exp Eye Res. 2001. PMID: 11825021
-
Clinical trial of docosahexaenoic acid in patients with retinitis pigmentosa receiving vitamin A treatment.Arch Ophthalmol. 2004 Sep;122(9):1297-305. doi: 10.1001/archopht.122.9.1297. Arch Ophthalmol. 2004. PMID: 15364708 Clinical Trial.
-
Current Pharmacological Concepts in the Treatment of the Retinitis Pigmentosa.Adv Exp Med Biol. 2018;1074:439-445. doi: 10.1007/978-3-319-75402-4_54. Adv Exp Med Biol. 2018. PMID: 29721974 Review.
-
[Early therapeutic trials for retinitis pigmentosa].Bull Acad Natl Med. 2003;187(9):1685-92; discussion 1692-4. Bull Acad Natl Med. 2003. PMID: 15369238 Review. French.
Cited by
-
Severe retinitis pigmentosa phenotype associated with novel CNGB1 variants.Am J Ophthalmol Case Rep. 2020 Jun 13;19:100780. doi: 10.1016/j.ajoc.2020.100780. eCollection 2020 Sep. Am J Ophthalmol Case Rep. 2020. PMID: 32613137 Free PMC article.
-
Optical Coherence Tomography Split-Spectrum Amplitude-Decorrelation Optoretinography Detects Early Central Cone Photoreceptor Dysfunction in Retinal Dystrophies.Transl Vis Sci Technol. 2024 Oct 1;13(10):5. doi: 10.1167/tvst.13.10.5. Transl Vis Sci Technol. 2024. PMID: 39361318 Free PMC article.
-
Delivery strategies for CRISPR/Cas genome editing tool for retinal dystrophies: challenges and opportunities.Asian J Pharm Sci. 2022 Mar;17(2):153-176. doi: 10.1016/j.ajps.2022.02.001. Epub 2022 Feb 13. Asian J Pharm Sci. 2022. PMID: 36320315 Free PMC article. Review.
-
A novel mutation of the RPGR gene in a Chinese X-linked retinitis pigmentosa family and possible involvement of X-chromosome inactivation.Eye (Lond). 2021 Jun;35(6):1688-1696. doi: 10.1038/s41433-020-01150-0. Epub 2020 Aug 24. Eye (Lond). 2021. PMID: 32839555 Free PMC article.
-
Biology and therapy of inherited retinal degenerative disease: insights from mouse models.Dis Model Mech. 2015 Feb;8(2):109-29. doi: 10.1242/dmm.017913. Dis Model Mech. 2015. PMID: 25650393 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases